Vimgreen's Novel A2AR Antagonist Receives CDE IND Approval for NASH/MASH Therapy

Vimgreen Pharmaceuticals, a leading innovator in adenosine signaling modulation, today announced the approval of its Investigational New Drug (IND) application for VG081821 in non‑alcoholic ...
Monthly Prescribing Reference

β-Catenin Antagonist Designated Orphan Drug for Familial Adenomatous Polyposis

ST316 interfered with β-catenin immune-exclusion allowing for stronger cytotoxic T-cell activity. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ST316 for the treatment ...
Seeking Alpha

Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model

Contineum Therapeutics, Inc. (CTNM) has been able to do well to advance the use of an LPA1R antagonist for the treatment of neuroinflammatory disorders in a phase 1 healthy volunteer study. Why ...
EurekAlert!

Computational frameworks transform antagonism to synergy in optimizing combination therapies

This study reveals that artificial intelligence can revolutionize combination therapies by converting ineffective or harmful drug interactions (antagonism) into highly cooperative treatments (synergy) ...